logo-loader
viewGenedrive PLC

Genedrive receives NHS grant to develop and implement point-of-care test

David Budd, chief executive of Genedrive PLC (LON:GDR) and Bill Newman, Professor of Translational Genomic Medicine at the University of Manchester discuss with Proactive Investors the grant awarded to Genedrive for a point-of-care pharmacogenetic test to avoid antibiotic-related hearing loss in newborn children.

The project's expected to commence immediately, with an expected development phase of one year followed by a trial implementation phase in selected NHS hospitals in year two.

Quick facts: Genedrive PLC

Price: 88.5 GBX

AIM:GDR
Market: AIM
Market Cap: £46.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genedrive's David Budd details launch of its unique coronavirus test kits...

Genedrive PLC's (LON:GDR) David Budd recaps on its two coronavirus test kits. The first, which was CE marked last week and they're in the process of launching, is a high-throughput lab-based PCR test which assesses whether someone's got an active infection. The second is a point-of-care version...

on 29/5/20

2 min read